Rein Therapeutics (RNTX)
NASDAQ:RNTX
Want to see RNTX full AI Analyst Report?
Top Page
Rein Therapeutics
(NASDAQ:RNTX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.93
▼(-26.35% Downside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by very weak financial performance (no revenue, large losses, and negative free cash flow) and bearish technicals (below major moving averages with negative MACD). Offsetting these, recent financing meaningfully improves operating runway into 2028, reducing near-term liquidity risk.
Positive Factors
Improved funding runway
The $50M offering and management's expectation that proceeds plus existing cash fund operations into 2028 materially reduces near-term liquidity risk. This allows uninterrupted execution of the Phase 2 LTI-03 program and gives time to reach clinical milestones without immediate financing pressure.
Negative Factors
No revenue, large losses
Rein reports no revenue and a TTM net loss of $50.2M, indicating the company has no commercialized products and relies on capital markets. Persistent sizable losses erode equity, increase dependence on financing, and make long-term sustainability contingent on clinical success rather than operational cash flow.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved funding runway
The $50M offering and management's expectation that proceeds plus existing cash fund operations into 2028 materially reduces near-term liquidity risk. This allows uninterrupted execution of the Phase 2 LTI-03 program and gives time to reach clinical milestones without immediate financing pressure.
Read all positive factors
Rein Therapeutics (RNTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$81.94M
Dividend YieldN/A
Average Volume (3M)228.95K
Price to Earnings (P/E)―
Beta (1Y)1.33
Revenue GrowthN/A
EPS Growth33.42%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding85,539,030
10 Day Avg. Volume262,542
30 Day Avg. Volume228,948
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.43
Forecast
1Y Price Target
$8.00Price Target Upside534.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Rein Therapeutics Business Overview & Revenue Model
Company Description
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is ...
How the Company Makes Money
null...
Rein Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
16
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -50.58M | -28.05M | -15.23K | -27.16K | -26.04K |
| Net Income | -49.87M | -62.88M | -15.73K | -27.33K | -26.16K |
Balance Sheet | |||||
| Total Assets | 24.16M | 69.24M | 106.01M | 22.01M | 48.48M |
| Cash, Cash Equivalents and Short-Term Investments | 3.21M | 12.87M | 17.31M | 21.24M | 45.93M |
| Total Debt | 0.00 | 0.00 | 48.00K | 33.00K | 162.00K |
| Total Liabilities | 7.24M | 14.85M | 99.12M | 3.38M | 4.58M |
| Stockholders Equity | 16.92M | 54.39M | 6.89M | 18.62M | 43.90M |
Cash Flow | |||||
| Free Cash Flow | -19.36M | -22.29M | -19.81M | -24.86M | -23.91M |
| Operating Cash Flow | -19.36M | -22.29M | -19.81M | -24.86M | -23.75M |
| Investing Cash Flow | 0.00 | 0.00 | 16.20M | 26.46M | -35.92M |
| Financing Cash Flow | 9.76M | 17.82M | 15.79M | 0.00 | 55.66M |
Rein Therapeutics Technical Analysis
Negative
1.26
Price Trends
1.26
Negative
1.26
Negative
1.29
Negative
Market Momentum
-0.08
Negative
37.15
Neutral
26.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNTX, the sentiment is Negative. The current price of 1.26 is above the 20-day moving average (MA) of 1.01, above the 50-day MA of 1.26, and below the 200-day MA of 1.29, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 37.15 is Neutral, neither overbought nor oversold. The STOCH value of 26.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNTX.
Rein Therapeutics Risk Analysis
Rein Therapeutics disclosed 68 risk factors in its most recent earnings report. Rein Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rein Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $169.66M | -0.98 | -61.02% | ― | ― | 25.85% | |
47 Neutral | $81.94M | -0.57 | -258.45% | ― | ― | 33.42% | |
47 Neutral | $94.16M | -4.70 | -245.45% | ― | 164.08% | 58.49% | |
43 Neutral | $7.95M | -0.34 | -335.47% | ― | 33.77% | -20.22% |
* Healthcare Sector Average
RNTX
Rein Therapeutics
0.94
-0.86
-47.67%
VVOS
Vivos Therapeutics
0.58
-1.58
-73.29%
OKUR
OnKure Therapeutics
4.20
1.78
73.55%
RANI
Rani Therapeutics Holdings
0.77
0.26
50.59%
Rein Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Rein Therapeutics Prices $50 Million Public Equity Offering
Positive
May 4, 2026
On April 30, 2026, Rein Therapeutics announced it had priced an underwritten public offering of 50 million shares of common stock at $1.00 per share, for gross proceeds of $50 million, with a 45-day option for underwriters to buy up to an addition...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.